Synergistic vascular protective effects of combined low doses of PPARα and PPARγ activators in angiotensin II-induced hypertension in rats

被引:28
作者
De Ciuceis, C.
Amiri, F.
Iglarz, M.
Cohn, J. S.
Touyz, R. M.
Schiffrin, E. L.
机构
[1] Sir Mortimer B Davis Jewish Hosp, Davis Inst Med Res, Vasc & Hypertens Res Unit, Montreal, PQ H3T 1E2, Canada
[2] Univ Montreal, Clin REs Inst, Hyperlipidemia & Atherosclerosis Res Grp, Montreal, PQ, Canada
[3] Univ Ottawa, Ottawa Hlth Res Inst, Kidney Res Ctr, Ottawa, ON, Canada
关键词
renin-angiotensin system; reactive oxygen species; inflammation; endothelial function; thiazolidinediones; fibrates;
D O I
10.1038/sj.bjp.0707215
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose: Protective cardiovascular effects of peroxisome proliferator activated receptor (PPAR)alpha and PPAR gamma activators have been demonstrated. If used as vasoprotective agents in high risk vascular patients rather than for their metabolic benefits, these agents could be associated with unwanted side effects. As a proof of concept to support the use of combined low doses of PPAR alpha and PPAR gamma as vascular protective agents in high risk vascular patients, we tested the hypothesis that combined low doses of PPAR alpha (fenofibrate) and PPAR gamma (rosiglitazone) activators would provide vascular protective benefits similar to full individual doses of these PPAR agonists. Experimental Approach: Male Sprague-Dawley rats infused with Ang II (120 ng kg(-1) min(-1)) were treated with rosiglitazone (1 or 2 mg kg(-1) day(-1)) alone or concomitantly with fenofibrate (30 mgkg(-1) day(-1)) for 7 days. Thereafter, vessels was assessed on a pressurized myograph, while NAD(P) H oxidase activity was determined by lucigenin chemiluminescence. Inflammation was evaluated using ELISA for NF kappa B and Western blotting for adhesion molecules. Key Results: Ang II-induced blood pressure increase, impaired acetylcholine-induced vasorelaxation, altered vascular structure, and enhanced vascular NAD(P) H oxidase activity and inflammation were significantly reduced by low dose rosiglitazone + fenofibrate. Conclusions and Implications: Combined low doses of PPARa and PPARg activators attenuated development of hypertension, corrected vascular structural abnormalities, improved endothelial function, oxidative stress, and vascular inflammation. These agents used in low-dose combination have synergistic vascular protective effects. The clinical effects of combined low-dose PPARa and PPARg activators as vascular protective therapy, potentially with reduced side-effects and drug interactions, should be assessed.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 38 条
[1]   Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction [J].
Amiri, F ;
Virdis, A ;
Neves, MF ;
Iglarz, M ;
Seidah, NG ;
Touyz, RM ;
Reudelhuber, TL ;
Schiffrin, EL .
CIRCULATION, 2004, 110 (15) :2233-2240
[2]   PPAR-γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1 [J].
Benkirane, K ;
Amiri, F ;
Diep, QN ;
El Mabrouk, M ;
Schiffrin, EL .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (01) :H390-H397
[3]   Peroxisome proliferator-activated receptor γ regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo [J].
Benkirane, K ;
Viel, ÉC ;
Amiri, F ;
Schiffrin, EL .
HYPERTENSION, 2006, 47 (01) :102-108
[4]   Ragaglitazar:: a novel PPARα & PPARδ agonist with potent lipidlowering and insulin-sensitizing efficacy in animal models [J].
Chakrabarti, R ;
Vikramadithyan, RK ;
Misra, P ;
Hiriyan, J ;
Raichur, S ;
Damarla, RK ;
Gershome, C ;
Suresh, J ;
Rajagopalan, R .
BRITISH JOURNAL OF PHARMACOLOGY, 2003, 140 (03) :527-537
[5]   Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice - Evidence for a role in inflammation in angiotensin-induced vascular injury [J].
De Ciuceis, C ;
Amiri, F ;
Brassard, P ;
Endemann, DH ;
Touyz, RM ;
Schiffrin, EL .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2106-2113
[6]   Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1 [J].
Delerive, P ;
De Bosscher, K ;
Besnard, S ;
Vanden Berghe, W ;
Peters, JM ;
Gonzalez, FJ ;
Fruchart, JC ;
Tedgui, A ;
Haegeman, G ;
Staels, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (45) :32048-32054
[7]   Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats -: Role of peroxisome proliferator-activated receptor-γ [J].
Diep, QN ;
El Mabrouk, M ;
Cohn, JS ;
Endemann, D ;
Amiri, F ;
Virdis, A ;
Neves, MF ;
Schiffrin, EL .
CIRCULATION, 2002, 105 (19) :2296-2302
[8]   PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats [J].
Diep, QN ;
Benkirane, K ;
Amiri, F ;
Cohn, JS ;
Endemann, D ;
Schiffrin, EL .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (02) :295-304
[9]   PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation [J].
Diep, QN ;
Amiri, F ;
Touyz, RM ;
Cohn, JS ;
Endemann, D ;
Neves, MF ;
Schiffrin, EL .
HYPERTENSION, 2002, 40 (06) :866-871
[10]   Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity [J].
Dobrian, AD ;
Schriver, SD ;
Khraibi, AA ;
Prewitt, RL .
HYPERTENSION, 2004, 43 (01) :48-56